Log In
BCIQ
Print this Print this
 

OP-233 (formerly TAK-233)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
Description 
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationIncontinence
Indication DetailsTreat stress urinary incontinence
Regulatory Designation
PartnerOutpost Medicine

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/15/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today